Clinical Trials Browser

Phase 1 × INDUSTRY × GSK2256098 × Clear all

NCT01938443 2019-07-12

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasmThoracic

Mesothelioma, Neoplasms

NCT00996671 2017-06-14

FTIH

Phase 1 Completed

Neoplasms

NCT01138033 2017-05-11

Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors

Phase 1 Completed

Neoplasms